OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles S. Berkman sold 8,215 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total value of $30,231.20. Following the transaction, the insider now directly owns 364,131 shares in the company, valued at $1,340,002.08. This represents a 2.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
OmniAb Price Performance
Shares of OABI traded down $0.23 during midday trading on Friday, hitting $3.65. 635,557 shares of the company traded hands, compared to its average volume of 508,669. OmniAb, Inc. has a one year low of $3.10 and a one year high of $6.55. The firm has a market cap of $515.45 million, a P/E ratio of -5.89 and a beta of -0.12. The stock has a 50-day moving average of $3.49 and a 200-day moving average of $3.91.
Analyst Ratings Changes
Several research firms have recently issued reports on OABI. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reiterated a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.
View Our Latest Research Report on OABI
Hedge Funds Weigh In On OmniAb
Several hedge funds have recently bought and sold shares of OABI. Hsbc Holdings PLC bought a new position in OmniAb in the 4th quarter valued at $38,000. Choreo LLC purchased a new stake in shares of OmniAb in the fourth quarter worth $41,000. Rangeley Capital LLC bought a new stake in OmniAb during the fourth quarter valued at $41,000. KLP Kapitalforvaltning AS bought a new stake in OmniAb during the fourth quarter valued at $49,000. Finally, CWC Advisors LLC. purchased a new position in OmniAb during the third quarter worth about $54,000. Hedge funds and other institutional investors own 72.08% of the company's stock.
OmniAb Company Profile
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Read More
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
